Abstract
Long-term clinical outcomes in patients with chronic hepatitis B virus (HBV) infection are assumed to be improved by therapy. However, because outcomes such as cirrhotic complications and hepatocellular carcinoma (HCC) take so long to occur, current treatment trials have assessed outcomes using surrogate endpoints, including biochemical response (normalization of alanine aminotransferase), virologic response (suppression of HBV DNA and seroconversion of hepatitis B e antigen), …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
